- Home
- ICCC vs OKYO Comparison
ICCC vs OKYO Comparison
Compare ICCC & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- OKYO
- Stock Information
- Founded
- ICCC 1982
- OKYO 2007
- Country
- ICCC United States
- OKYO United Kingdom
- Employees
- ICCC N/A
- OKYO N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCC Health Care
- OKYO Health Care
- Exchange
- ICCC Nasdaq
- OKYO Nasdaq
- Market Cap
- ICCC 39.2M
- OKYO 37.0M
- IPO Year
- ICCC 1987
- OKYO 2022
- Fundamental
- Price
- ICCC $5.02
- OKYO $1.12
- Analyst Decision
- ICCC
- OKYO Strong Buy
- Analyst Count
- ICCC 0
- OKYO 1
- Target Price
- ICCC N/A
- OKYO $7.00
- AVG Volume (30 Days)
- ICCC 4.1K
- OKYO 273.5K
- Earning Date
- ICCC 02-25-2025
- OKYO 03-04-2025
- Dividend Yield
- ICCC N/A
- OKYO N/A
- EPS Growth
- ICCC N/A
- OKYO N/A
- EPS
- ICCC N/A
- OKYO N/A
- Revenue
- ICCC $23,838,001.00
- OKYO N/A
- Revenue This Year
- ICCC N/A
- OKYO N/A
- Revenue Next Year
- ICCC N/A
- OKYO N/A
- P/E Ratio
- ICCC N/A
- OKYO N/A
- Revenue Growth
- ICCC 46.37
- OKYO N/A
- 52 Week Low
- ICCC $3.34
- OKYO $0.81
- 52 Week High
- ICCC $5.82
- OKYO $1.90
- Technical
- Relative Strength Index (RSI)
- ICCC 47.31
- OKYO 54.76
- Support Level
- ICCC $4.84
- OKYO $1.01
- Resistance Level
- ICCC $5.25
- OKYO $1.13
- Average True Range (ATR)
- ICCC 0.27
- OKYO 0.06
- MACD
- ICCC -0.04
- OKYO 0.00
- Stochastic Oscillator
- ICCC 27.27
- OKYO 61.76
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.